FibroBiologics, Common Total Current Liabilities Over Time
| FBLG Stock | 2.22 0.07 3.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out FibroBiologics, Common Performance and FibroBiologics, Common Correlation. FibroBiologics, |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare FibroBiologics, Common and related stocks such as ReTo Eco Solutions, MYR Group, and Newpark Resources Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RETO | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.3 M | 28.1 M | 26.6 M | 20.7 M | 25.2 M | 23 M | 16.8 M | 17.7 M | 17.3 M | 17.6 M |
| MYRG | 10 M | 176.8 M | 188.9 M | 204.4 M | 171.6 M | 179.7 M | 228.3 M | 188.6 M | 283.8 M | 396.8 M | 443.4 M | 498.6 M | 667 M | 747.2 M | 784.6 M |
| NR | 25.4 M | 146.8 M | 159.6 M | 153.8 M | 173.2 M | 125.4 M | 179.8 M | 158.4 M | 141.9 M | 128.9 M | 153.7 M | 150.4 M | 162.9 M | 136.3 M | 103.1 M |
| CPAC | 201.6 M | 309.1 M | 179.8 M | 157.7 M | 200.1 M | 203.5 M | 180.7 M | 205 M | 258.6 M | 352.7 M | 265.1 M | 722.2 M | 953.1 M | 689.4 M | 376.8 M |
| RBC | 37.5 M | 43.9 M | 46.6 M | 42.8 M | 42 M | 88.3 M | 93.1 M | 105.2 M | 90.1 M | 103.8 M | 88.2 M | 313.5 M | 309.3 M | 294.3 M | 309 M |
| NBR | 21.3 M | 1.8 B | 1.1 B | 1.3 B | 1.6 B | 1 B | 821.9 M | 919.5 M | 832.1 M | 656.5 M | 515.5 M | 525.2 M | 596.4 M | 1.2 B | 708.6 M |
FibroBiologics, Common and related stocks such as ReTo Eco Solutions, MYR Group, and Newpark Resources Total Current Liabilities description
Total Current Liabilities is an item on FibroBiologics, Common balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of FibroBiologics, Common Stock are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
| FibroBiologics, Common Stock | FBLG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
null 2.22
Check out FibroBiologics, Common Performance and FibroBiologics, Common Correlation. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
FibroBiologics, Common technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.